The panel unanimously said that the benefits of Moderna's mRNA jab outweigh its risks in preventing influenza in certain age groups.

The vaccine, intended for people 50 and older, is based on mRNA technology and was found in an advanced trial to be more effective than a standard flu shot.

A meta-analysis indicates HD-IIV is superior to SD-IIV for reducing hospitalizations in adults aged 65 years and older.

By Christy Santhosh and Mariam Sunny June 18 (Reuters) - Advisers to the U.S. Food and Drug Administration on Thursday backed approval of Moderna's flu vaccine for adults aged 50 and older, saying its ...

Moderna's mRNA flu vaccine could be approved by August, but federal policy and a nonfunctional advisory committee threaten ...

The FluMist Home vaccine will simply be the home version of the FluMist influenza vaccine that Tia Mowry is seen getting here. (Photo by Christopher Polk/Getty Images for FluMist Quadrivalent) These ...

New research comparing four different flu vaccines found that the ability of the vaccines to activate cells of the immune system that help to protect against infection varied greatly depending on the ...

Suppose you were designing an experiment to assess the effectiveness of the flu vaccine at preventing flu outbreaks. You’d want a population of test subjects, under consistent observation, in ...

Amid a worsening flu outbreak at Lackland Air Force Base in San Antonio, Texas, the U.S. Air Force, Army and Navy are once again requiring new recruits to get vaccinated against the influenza virus, ...

The commission said it was concerned the company’s campaign to promote its Efluelda flu vaccine might amount to ...